Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
Lila Sciences is looking to use $200 million in seed funding to develop advanced AI that can power fully autonomous research ...
Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of ...
Under President Donald Trump’s administration, the Department of Government Efficiency (DOGE) has reportedly terminated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results